Barclays analyst Andrew Mok has maintained an "Overweight" rating for CVS Health (CVS, Financial), as per the latest report dated May 2, 2025. The investment bank has increased the target price for the healthcare company from its previous mark of $73.00 to a new target of $82.00.
This adjustment signifies a 12.33% increase in the target price, aligning with Barclays’ optimistic outlook on CVS Health (CVS, Financial). The company continues to hold an "Overweight" rating, suggesting that the analyst expects the stock to perform better than the overall market.
The target price adjustment by Barclays could be an indicator of the bank's increased confidence in CVS Health's (CVS, Financial) business prospects and future growth potential. Investors in CVS (CVS) may find this updated target price as a positive signal regarding the company's market performance outlook.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 24 analysts, the average target price for CVS Health Corp (CVS, Financial) is $75.55 with a high estimate of $90.00 and a low estimate of $64.00. The average target implies an upside of 8.64% from the current price of $69.54. More detailed estimate data can be found on the CVS Health Corp (CVS) Forecast page.
Based on the consensus recommendation from 29 brokerage firms, CVS Health Corp's (CVS, Financial) average brokerage recommendation is currently 2.2, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for CVS Health Corp (CVS, Financial) in one year is $88.14, suggesting a upside of 26.75% from the current price of $69.54. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the CVS Health Corp (CVS) Summary page.
